J.P. Morgan Healthcare Conference Presentation
Trust: Delivering health impact sustainably
For health impact, shareholder returns and thriving people.
Six areas of focus for ESG engagement
Recent highlights
Access
Environment
Global health and
health security
Diversity, equity
and inclusion
Product governance
Ethical standards
Low carbon version of Ventolin metered dose inhaler
Phase III trials to start in 2024 on low carbon version of Ventolin which currently
accounts for half of GSK's carbon footprint
If successful, could reduce greenhouse gas emissions by ~90%
Pharma industry leader on S&P Global Corporate Sustainability Assessment
Annual evaluation of companies' ESG practices
Pharma sector is one of the most competitive industries
For 2023, GSK was named in leading position
Net zero targets verified by the Science Based Target Initiative's (SBTi)
Corporate Net-Zero Standard
Targets include 80% reduction in greenhouse gas emissions by 2030 and
90% reduction by 2045
Aim to address the remaining emissions through high quality offsets
GSK
ESG: Environment, Social and Governance
10View entire presentation